Apixaban meets VTE endpoint

Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) reported that apixaban was superior to Lovenox enoxaparin on the primary endpoint

Read the full 219 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE